[
  {
    "ts": null,
    "headline": "Merck Announces Second-Quarter 2026 Dividend",
    "summary": "RAHWAY, N.J., January 27, 2026--Merck Announces Second-Quarter 2026 Dividend",
    "url": "https://finnhub.io/api/news?id=7522592873cfe7cb91475ad01bd84e4f25f966c5050af79a7b60d737bc0adb18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769544420,
      "headline": "Merck Announces Second-Quarter 2026 Dividend",
      "id": 138275362,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., January 27, 2026--Merck Announces Second-Quarter 2026 Dividend",
      "url": "https://finnhub.io/api/news?id=7522592873cfe7cb91475ad01bd84e4f25f966c5050af79a7b60d737bc0adb18"
    }
  },
  {
    "ts": null,
    "headline": "3 Healthcare ETFs to Buy as Flat Medicare Rate Proposal Hits Insurers",
    "summary": "Flat Medicare Advantage rate hikes hit insurers hard, but diversified healthcare ETFs may help investors weather the policy shock.",
    "url": "https://finnhub.io/api/news?id=016c029863ceca3d956156f9ccea70c04c5fd5cec0c2a5ae73ccfb7d452ae0a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769543460,
      "headline": "3 Healthcare ETFs to Buy as Flat Medicare Rate Proposal Hits Insurers",
      "id": 138275301,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Flat Medicare Advantage rate hikes hit insurers hard, but diversified healthcare ETFs may help investors weather the policy shock.",
      "url": "https://finnhub.io/api/news?id=016c029863ceca3d956156f9ccea70c04c5fd5cec0c2a5ae73ccfb7d452ae0a6"
    }
  },
  {
    "ts": null,
    "headline": "RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer",
    "summary": "Revolution Medicines stock tanks after a WSJ report said Merck has withdrawn from buyout talks over price.",
    "url": "https://finnhub.io/api/news?id=a7f04f4952cb489ecc7e7f82b806d0016784a15234305d44284c63cc67b0715d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769529180,
      "headline": "RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer",
      "id": 138272466,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Revolution Medicines stock tanks after a WSJ report said Merck has withdrawn from buyout talks over price.",
      "url": "https://finnhub.io/api/news?id=a7f04f4952cb489ecc7e7f82b806d0016784a15234305d44284c63cc67b0715d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer, Merck, CoreWeave, Zoom: Top Analyst Calls",
    "summary": "Yahoo Finance Senior Reporter Brooke DiPalma keeps track of several Wall Street analyst calls on top trending stocks, including calls around shares of Pfizer (PFE), Merck (MRK), CoreWeave (CRWV), and Zoom Communications (ZM).To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=3c021d39f2ac0cdf89bf17d1d9b9d2259519371cc542bb4e1652b817b840653e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769528721,
      "headline": "Pfizer, Merck, CoreWeave, Zoom: Top Analyst Calls",
      "id": 138270994,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Yahoo Finance Senior Reporter Brooke DiPalma keeps track of several Wall Street analyst calls on top trending stocks, including calls around shares of Pfizer (PFE), Merck (MRK), CoreWeave (CRWV), and Zoom Communications (ZM).To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=3c021d39f2ac0cdf89bf17d1d9b9d2259519371cc542bb4e1652b817b840653e"
    }
  },
  {
    "ts": null,
    "headline": "2 Pharmaceutical Stocks Set to Rebound in 2026",
    "summary": "There might be massive upside ahead for these drugmakers.",
    "url": "https://finnhub.io/api/news?id=aaa89cb2519f9decf80e8e346fda46bfdffd302a91bc733619d8e5279bdd88fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769528220,
      "headline": "2 Pharmaceutical Stocks Set to Rebound in 2026",
      "id": 138270995,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "There might be massive upside ahead for these drugmakers.",
      "url": "https://finnhub.io/api/news?id=aaa89cb2519f9decf80e8e346fda46bfdffd302a91bc733619d8e5279bdd88fe"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
    "summary": "Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=a6782cdb311e2491c92c9efc4c33cd411f657554b98e3ad9e355f1eace565dc3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769526004,
      "headline": "Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
      "id": 138272505,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=a6782cdb311e2491c92c9efc4c33cd411f657554b98e3ad9e355f1eace565dc3"
    }
  },
  {
    "ts": null,
    "headline": "Revolution Medicines (RVMD) Dives 16.9% as Merck Withdraws Takeover Plan",
    "summary": "We recently published 10 Big Names Stumbling Hard. Revolution Medicines Inc. (NASDAQ:RVMD) was one of the worst performers on Monday. Revolution Medicines fell sharply on Monday, losing 16.91 percent to close at $97.78 apiece, as investors unloaded portfolios following news that pharmaceutical giant Merck had cancelled ongoing negotiations for its proposed acquisition of the company. […]",
    "url": "https://finnhub.io/api/news?id=ddfa0cf34cfd164b6dd84b2aba43331d8d75d6cf54924af0c6743828b392811c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769508155,
      "headline": "Revolution Medicines (RVMD) Dives 16.9% as Merck Withdraws Takeover Plan",
      "id": 138269278,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published 10 Big Names Stumbling Hard. Revolution Medicines Inc. (NASDAQ:RVMD) was one of the worst performers on Monday. Revolution Medicines fell sharply on Monday, losing 16.91 percent to close at $97.78 apiece, as investors unloaded portfolios following news that pharmaceutical giant Merck had cancelled ongoing negotiations for its proposed acquisition of the company. […]",
      "url": "https://finnhub.io/api/news?id=ddfa0cf34cfd164b6dd84b2aba43331d8d75d6cf54924af0c6743828b392811c"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s (MRK) Quality is Clear, but Growth Visibility Matters, TD Cowen Notes",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. On January 20, TD Cowen analyst Steve Scala raised Merck & Co., Inc. (NYSE:MRK) price target to $120 from $100. The firm maintained a Hold rating. The analyst acknowledged that Merck is a strong and well-run […]",
    "url": "https://finnhub.io/api/news?id=af3a71dd76b95e159ae124c7c576b61a66acc301092f1623ad2b01f5957b9ef7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769498067,
      "headline": "Merck’s (MRK) Quality is Clear, but Growth Visibility Matters, TD Cowen Notes",
      "id": 138268117,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. On January 20, TD Cowen analyst Steve Scala raised Merck & Co., Inc. (NYSE:MRK) price target to $120 from $100. The firm maintained a Hold rating. The analyst acknowledged that Merck is a strong and well-run […]",
      "url": "https://finnhub.io/api/news?id=af3a71dd76b95e159ae124c7c576b61a66acc301092f1623ad2b01f5957b9ef7"
    }
  },
  {
    "ts": null,
    "headline": "Bernstein Calls 2026 a “Waiting Year” for Amgen’s (AMGN) MariTide",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. On January 20, Bernstein downgraded Amgen Inc. (NASDAQ:AMGN) to Market Perform from Outperform, while leaving its $335 price target unchanged. The firm said the decision was mainly driven by its view that “2026 is a waiting year” for […]",
    "url": "https://finnhub.io/api/news?id=f4d7b0a26cfd02dd2f9531e4c5192ee16ea59cd17e447e8dcf071d43559b325f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769496756,
      "headline": "Bernstein Calls 2026 a “Waiting Year” for Amgen’s (AMGN) MariTide",
      "id": 138268118,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. On January 20, Bernstein downgraded Amgen Inc. (NASDAQ:AMGN) to Market Perform from Outperform, while leaving its $335 price target unchanged. The firm said the decision was mainly driven by its view that “2026 is a waiting year” for […]",
      "url": "https://finnhub.io/api/news?id=f4d7b0a26cfd02dd2f9531e4c5192ee16ea59cd17e447e8dcf071d43559b325f"
    }
  },
  {
    "ts": null,
    "headline": "Why Revolution Medicines Stock Plummeted by Almost 17% Today",
    "summary": "It doesn't look like the company will end up in the arms of an acquirer soon, after all.",
    "url": "https://finnhub.io/api/news?id=f0735ca5ac0be7f36fc889e548b705e71e227ccd42db2e0ce47cb858353c8e00",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769474191,
      "headline": "Why Revolution Medicines Stock Plummeted by Almost 17% Today",
      "id": 138266025,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "It doesn't look like the company will end up in the arms of an acquirer soon, after all.",
      "url": "https://finnhub.io/api/news?id=f0735ca5ac0be7f36fc889e548b705e71e227ccd42db2e0ce47cb858353c8e00"
    }
  }
]